Low plasma vitamin A concentrations in familial combined hyperlipidemia

Clinical Chemistry

Volumn 43, Issue 12, 1997, Pages 2379-2383

  Ribalta, Josep ^a   La Ville, Agnes E ^a   Girona, Josefa ^a   Vallvé, Joan C ^a   Masana, Lluís ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN C3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PHENOTYPE; TURBIDIMETRY; ULTRACENTRIFUGATION; VITAMIN BLOOD LEVEL;

EID: 15444360810     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.12.2379     Document Type: Article

References (27)

1. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipidemia: evidence for a new lipoprotein phenotype. J Lipid Res 1973;54:148-60.
2. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II: Genetic analyses of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68.
3. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24: 147-55.
4. Kwiterovich PO. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 1993;4:133-43.
5. Janus ED, Nicoll AM, Turner PR, Magill P, Lewis B. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 1980;10: 161-72.
6. Austin MA, Horowitz H, Wijsman E, Krauss RM, Brunzell J. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis 1992;92:67-77.
7. Babirak SP, Iverius P-H, Fujimoto WY, Brunzell JD. Detection and characterisation of the heterozygote state of lipoprotein lipase deficiency. Arteriosclerosis 1989;9:326-334.
8. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscl Thromb 1992; 12:1176-83.
9. Castro-Cabezas M, de Bruin TWA, Jansen H, Kock AW, Kortland W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:804-14.
10. Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, et al. A common variant in the gene for lipoprotein lipase (Asp9→Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscl Thromb Vasc Biol 1995; 15:468-78.
11. Reymer PW, Groenemeyer BE. Gagné E, Miao L, Appelman EEG, Seidel JC, et al. A frequently occurring mutation in the lipoprotein lipase gene (Asn291→Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet 1995;4:1543-9.
12. Xu CF, Talmud P, Schuster H, Houlston R, Miller G, Humphries S. Association between genetic variation in the AI-CIII-AIV gene cluster and familial combined hyperlipidemia. Clin Genet 1994; 46:385-97.
13. Dallinga-Thie G, Bu X-D, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996;37:136-47.
14. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest 1995;95:705-12.
15. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARa and PPARg activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48.
16. Auwerx J, Schoonjans K, Fruchart JC, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996;124:S29-S37.
17. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302: 93-109.
18. Schumaker VR, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol 1986;128:155-70.
19. Bieri JC, Tolliver TJ, Catignani GL. Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Am J Clin Nutr 1979;10:2143-9.
20. Kosykh VA, Podrez EA, Novikov DK, Victorov AV, Dolbin AG, Repin VS, Smirnov VN. Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes. Atherosclerosis 1987;68:67-76.
21. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, et al. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979;301:1073-6.
22. Goodman DW. Vitamin A, retinoids in health and disease. N Engl J Med 1984;310:1023-30.
23. Blomhoff R, Green M, Morum K. Vitamin A. Physiological and biochemical processing. Ann Rev Nutr 1990;49:1-12.
24. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295-308.
25. Nagasaki A, Kikuchi T, Kurata K, Masushige S, Hasegawa T, Kato S. Vitamin A regulates the expression of apolipoprotein AI and CIII genes in the rat. Biochem Biophys Res Commun 1994;205: 1510-7.
26. Cohen PR. The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia. Clin Invest 1993;71:74-7.
27. Omenn GS, Goodman GE, Thornquist M, Brunzell JD. Long-term vitamin A does not produce clinically significant hypertriglyceridemia: results from CARET, the beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 1994;3:711-3.